title: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
abstract: To determine whether molecular parameters could be partly responsible for resistance or sensitivity to oxaliplatin (OX)-based chemotherapy used as first-line treatment in advanced colorectal cancer (CRC). We studied the usefulness of the excision repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD), XRCC1 and GSTP1 polymorphisms as predictors of clinical outcome in these patients. We treated 126 CRC patients with a first-line OX/5-fluorouracil chemotherapeutic regimen. Genetic polymorphisms were determined by real-time PCR on an ABI PRISM 7000, using DNA from peripheral blood. Clinical response (CR), progression-free survival (PFS) and overall survival (OS) were evaluated according to each genotype. In the univariate analysis for CR, ERCC1-118 and XPD 751 polymorphisms were significant (P=0.02 and P=0.05, respectively). After adjustment for the most relevant clinical variables, only ERCC1-118 retained significance (P=0.008). In the univariate analysis for PFS, ERCC1-118 and XPD 751 were significant (P=0.003 and P=0.009, respectively). In the multivariant analysis, only the XPD 751 was significant for PFS (P=0.02). Finally, ERCC1-118 and XPD 751 polymorphisms were significant in the univariate analysis for OS (P=0.006 and P=0.015, respectively). Both genetic variables remained significant in the multivariate Cox survival analysis (P=0.022 and P=0.03). Our data support the hypothesis that enhanced DNA repair diminishes the benefit of platinum-based treatments.
authors.affiliation: Department of Genetics, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona [corrected] Barcelona 08025, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Paré
authors.forename: E
authors.initials: E
authors.lastname: Marcuello
authors.forename: A
authors.initials: A
authors.lastname: Altés
authors.forename: E
authors.initials: E
authors.lastname: del Río
authors.forename: L
authors.initials: L
authors.lastname: Sedano
authors.forename: J
authors.initials: J
authors.lastname: Salazar
authors.forename: A
authors.initials: A
authors.lastname: Cortés
authors.forename: A
authors.initials: A
authors.lastname: Barnadas
authors.forename: M
authors.initials: M
authors.lastname: Baiget
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D004268:DNA-Binding Proteins / Q000235:genetics; D018572:Disease-Free Survival; D004720:Endonucleases / Q000235:genetics; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005982:Glutathione Transferase / Q000235:genetics; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010597:Pharmacogenetics; D016133:Polymerase Chain Reaction; D016896:Treatment Outcome; D000076105:X-ray Repair Cross Complementing Protein 1
chemical_list: D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human; D000077150:Oxaliplatin; D005982:Glutathione Transferase; C071447:ERCC1 protein, human; D004720:Endonucleases; D005472:Fluorouracil
references.citation: Ann Oncol. 2002 Feb;13(2):308-17
references.pmid: 11886010
references.citation: Cancer Res. 2001 Dec 15;61(24):8654-8
references.pmid: 11751380
references.citation: Br J Cancer. 2006 Jul 17;95(2):131-8
references.pmid: 16835584
references.citation: J Natl Cancer Inst. 1990 Jun 20;82(12):1046-50
references.pmid: 2348469
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6212-7
references.pmid: 16144923
references.citation: Mutat Res. 1997 Sep;382(1-2):13-20
references.pmid: 9360634
references.citation: Toxicology. 2003 Nov 15;193(1-2):35-41
references.pmid: 14599766
references.citation: Int J Oncol. 2000 Mar;16(3):555-60
references.pmid: 10675489
references.citation: Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12
references.pmid: 9609103
references.citation: Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):289-92
references.pmid: 10207630
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6100-2
references.pmid: 16144907
references.citation: Cancer Res. 2003 Dec 1;63(23):8097-102
references.pmid: 14678959
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2101-8
references.pmid: 16609022
references.citation: Bioinformatics. 2003 Nov 1;19(16):2147-8
references.pmid: 14594722
references.citation: Clin Cancer Res. 2006 May 15;12(10):3050-6
references.pmid: 16707601
references.citation: J Clin Oncol. 2007 Apr 1;25(10):1247-54
references.pmid: 17401013
references.citation: Anticancer Res. 2001 Jul-Aug;21(4B):3075-9
references.pmid: 11712813
references.citation: J Clin Oncol. 2001 Dec 1;19(23):4298-304
references.pmid: 11731512
references.citation: Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6
references.pmid: 16224397
references.citation: Nucleic Acids Res. 1988 Feb 11;16(3):1215
references.pmid: 3344216
references.citation: Br J Cancer. 2004 Jul 19;91(2):344-54
references.pmid: 15213713
references.citation: Carcinogenesis. 1998 Feb;19(2):275-80
references.pmid: 9498276